Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Fox Chase Cancer Center
Stanford University
University of Erlangen-Nürnberg Medical School
National Cancer Institute (NCI)
The University of Texas Health Science Center, Houston